Related Experiment Video
Updated: Jul 11, 2025

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
Increased Left Ventricular End-Diastolic Volume Index Is Associated With Increased Adverse Events After MitraClip
Masafumi Yoshikawa1, Hiroyuki Arashi1, Noriko Kikuchi1
1Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
Insights
Higher left ventricular end-diastolic volume index (LVEDVI) is linked to increased adverse events after MitraClip procedures for severe mitral regurgitation. This finding highlights LVEDVI as a potential predictor of poor outcomes in these patients.
Area of Science:
- Cardiology
- Medical Devices
- Clinical Outcomes
Background:
- Severe mitral regurgitation poses significant clinical challenges.
- The MitraClip procedure offers a less invasive treatment option.
- Predictors of adverse events post-MitraClip require further investigation.
Purpose of the Study:
- To examine the association between left ventricular end-diastolic volume index (LVEDVI) and adverse clinical events after MitraClip implantation.
- To identify a potential LVEDVI threshold for predicting poor outcomes in this patient cohort.
Main Methods:
- Retrospective observational study of 123 patients undergoing MitraClip.
- Receiver operating characteristic (ROC) curve analysis to determine LVEDVI cut-off.
- Comparison of primary end points (all-cause mortality, heart failure hospitalization) between LVEDVI groups.
Main Results:
- An LVEDVI cut-off of 118 ml/m² was identified.
- Patients with LVEDVI ≥118 ml/m² had a significantly higher incidence of adverse events (41.9%) compared to those with LVEDVI <118 ml/m² (24.6%).
- Increased LVEDVI remained an independent predictor of adverse events (HR 2.24, p=0.01), even after adjustment for confounders.
Conclusions:
- Elevated LVEDVI is associated with a greater risk of adverse clinical events following MitraClip implantation.
- LVEDVI may serve as a valuable prognostic marker in patients treated with MitraClip for severe mitral regurgitation.
Abstract:
This study investigated the association between the left ventricular end-diastolic volume index (LVEDVI) and the incidence of adverse clinical events in patients after MitraClip implantation. In this retrospective, observational study, 123 patients who underwent the MitraClip procedure were enrolled. Participants were divided into 2 groups according to the LVEDVI cut-off level, calculated using receiver operating characteristic curve analysis, to predict the primary end point and the occurrence of cardiovascular events was compared between the groups. The primary end point was all-cause mortality and hospitalization because of heart failure. The receiver operating characteristic curve analysis for the composite primary end point revealed an LVEDVI cut-off point of 118 ml/m2. Based on this threshold, 61 patients (49.6%) were categorized into the LVEDVI <118 ml/m2 group, whereas 62 (50.4%) fell into the LVEDVI ≥118 ml/m2 group. Over a median follow-up period of 336 days (interquartile range 80 to 667), the primary end points occurred in 15 and 26 patients in the LVEDVI <118 and LVEDVI ≥118 ml/m2 groups, corresponding to incidence rates of 24.6% and 41.9%, respectively. Patients in the LVEDVI ≥118 ml/m2 group demonstrated a significantly higher risk of adverse clinical events than those in the LVEDVI <118 ml/m2 group (hazard ratio 2.24, 95% confidence interval 1.17 to 4.28, p = 0.01). This trend persisted even after adjusting for several confounders (p = 0.02). In conclusion, increased LVEDVI values were associated with increased adverse clinical events after MitraClip implantation in patients with severe mitral valve regurgitation.
More Related Videos
Related Concept Videos
Mitral Stenosis I: Introduction
Mitral Regurgitation I: Introduction
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Valve Prolapse II: Assessment and Management
Mitral Valve Prolapse I: Introduction
Mitral Regurgitation II: Clinical Features and Diagnostic Tests

